Literature DB >> 10232475

Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer.

I J Mertens1, J M De Klerk, P M Zelissen, J H Thijssen, D M Sie-Go, S H Han, P P Van Rijk.   

Abstract

The case of a 54-year-old woman with metastatic follicular thyroid cancer and undetectable serum thyroglobulin is presented. Many years after the patient had a subtotal thyroidectomy for a large goiter that had no clear evidence of malignancy, metastatic bone disease developed. When the bone metastases were detected and during the follow-up period, serum thyroglobulin values remained undetectable, but radioiodine uptake in the metastases was abundant. This case indicates that the combination of 1-131 scintigraphy and serum thyroglobulin values is superior to the measurement of serum thyroglobulin alone in detecting well-differentiated, metastatic thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232475     DOI: 10.1097/00003072-199905000-00011

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan.

Authors:  C Ceccarelli; F Bianchi; D Trippi; F Brozzi; F Di Martino; P Santini; R Elisei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

3.  Micrometastasis of papillary thyroid carcinoma in a human immunodeficiency virus-infected patient: a case report and discussion.

Authors:  Célia Lloret Linares; Didier Troisvallets; Pierre Sellier; André Aurengo; Laurence Leenhardt
Journal:  Med Oncol       Date:  2009-08-06       Impact factor: 3.064

4.  Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.

Authors:  A Golger; T R Fridman; S Eski; I J Witterick; J L Freeman; P G Walfish
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

5.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

Review 6.  Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

7.  Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients.

Authors:  Alfredo Campennì; Luca Giovanella; Salvatore Antonio Pignata; Antonio Vento; Angela Alibrandi; Letterio Sturiale; Riccardo Laudicella; Alessio Danilo Comis; Rossella Filice; Giuseppe Giuffrida; Maria Elena Stipo; Salvatore Giovinazzo; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Sergio Baldari
Journal:  Oncotarget       Date:  2018-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.